Basiliximab

Intravenous
Prophylaxis of acute graft rejection in renal transplantation

Reconstitute 10 mg and 20 mg vial w/ 2.5 mL and 5 mL sterile water for inj, respectively. To prepare the soln for infusion, further dilute w/ 25 mL (10 mg) or 50mL (20 mg) NaCl 0.9% soln or dextrose 5% in water.

Re-exposure to a subsequent course of therapy in patient who has previously received basiliximab. Childn. Pregnancy and lactation.

Anaphylaxis and other severe, acute hypersensitivity reactions (e.g. hypotension, tachycardia, cardiac failure, dyspnoea, wheezing, bronchospasm, pulmonary oedema, resp failure, urticaria, rash, pruritus, sneezing), lymphoproliferative disorders, opportunistic infections; constipation, nausea, diarrhoea, abdominal pain, vomiting, dyspepsia, enlarged abdomen, esophagitis, flatulence, gastroenteritis, GI hemorrhage, gum hyperplasia, melaena, moniliasis, ulcerative stomatitis; pain, peripheral oedema, fever, accidental trauma, asthenia, fatigue, malaise, rigors, sepsis; hyperkalaemia, hypokalaemia, hyperuricaemia, hypophosphataemia, hypercholesterolaemia, acidosis, dehydration, DM, fluid overload, hypercalcaemia, hyperlipaemia, hypertriglyceridaemia, hypocalcaemia, hypoglycaemia, hypomagnesaemia, hypoproteinaemia, wt gain; headache, tremor, dizziness, neuropathy, paraesthesia, hypoaesthesia; UTI, albuminuria, dysuria, haematuria, oliguria, abnormal renal function, renal tubular necrosis, urinary retention, ureteral disorder; HTN; acne; insomnia; anaemia, polycythaemia; haematoma, haemorrhage, purpura, thrombocytopenia, thrombosis; arrhythmia, atrial fibrillation; arthralgia, arthropathy, back pain, bone fracture, cramps, hernia, myalgia, leg pain; impotence; cataract, conjunctivitis, abnormal vision; hypertrichosis, skin ulceration.

Monitor signs and symptoms of acute rejection, infection and hypersensitivity; cardiorespiratory and renal function.

May diminish response to inactivated vaccines. May enhance the adverse/toxic effect of live vaccines, avoid concomitant admin.

Description: Basiliximab is a chimeric murine/human monoclonal antibody. It blocks the α-chain (CD25 antigen) of the interleukin-2 receptor complex on the surface of activated T-lymphocytes.
Duration: 36 days ± 14 days.
Pharmacokinetics:
Distribution: Volume of distribution: 8.6 ± 4.1 L.
Excretion: Terminal half-life: 7 days.

Store between 2-8°C. Reconstituted soln: 2-8°C for 24 hr or 4 hr at room temp.

Immunosuppressants

L04AC02 - basiliximab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

Anon. Basiliximab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/08/2016.

Buckingham R (ed). Basiliximab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/08/2016.

Joint Formulary Committee. Basiliximab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/08/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Basiliximab. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 08/08/2016.

Simulect inj, powder, for solution (Novartis Pharmaceuticals Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/08/2016.

Wickersham RM. Basiliximab. Facts and Comparisons [online]. St. Louis, MO. Wolters Kluwer Clinical Drug Information, Inc. https://www.wolterskluwercdi.com/facts-comparisons-online/. Accessed 30/08/2016.